TXG
10x Genomics, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$65.29
+5.94%Price chart
Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3
Key dataNov 3, 2026
Open$63.21
From 52W high−33.20%
Volume2.61M
Market cap$8.51B
P/E (TTM)—
P/S (TTM)13.8x
Div yield—
Key dataNov 3, 2026
Open
$63.21
From 52W high
−33.20%
Volume
2.61M
Market cap
$8.51B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
213.3x
P/E (TTM)
—
RSI (14)
41.6
MomentumView details →
1D Return
+5.94%
YTD Return
+298.10%
SummaryUpdated Jun 1, 2026
10x Genomics, Inc. (NASDAQ:TXG) is a life sciences technology company founded in 2012 and headquartered in Pleasanton, California. The company went public in September 2019 and has established itself as a leading provider of advanced genomics analysis tools. 10x Genomics develops and commercializes sophisticated instruments, consumables, and software that enable researchers to analyze biological systems at the cellular level with unprecedented detail. The company serves academic institutions, government research facilities, biotechnology companies, and pharmaceutical organizations across North America, Europe, the Middle East, Africa, China, and the Asia Pacific region.
Similar companies
Latest newsMore news →
10x Genomics appointed Joseph Gilliam chair of its 10x Genomics, Inc., effective October 30, 2026.2d ago10x Genomics appointed Ansuman Satpathy and Joseph Gilliam as Class III directors, effective October 28, 2026.2d ago10x Genomics, Inc. commercially launched Sentira Single Cell, a cloud-based application for analyzing Chromium data using natural-language prompts and powered by Anthropic PBC's Claude.2d ago